Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.
The Generic Pharmaceutical Association announced its support of Georgia SB 370, introduced by pharmacist and Sen. Buddy Carter, R-Ga. District 1, because it will allow unimpeded patient access to interchangeable biologics.
Bi-Lo on Thursday announced that all in-store pharmacies now offer “Refill Sync,” a free service that synchronizes customers’ maintenance medication prescriptions so that all scripts — regardless of refill dates — can be filled at the same time.
In a report released by the U.S. Government Accountability Office, the GAO found that the total draft federal upper limits amount based on the new formula under the Patient Protection and Affordable Care Act was about 1.4% lower than the total National Average Drug Acquisition Cost amount in aggregate for 1,035 outpatient drugs subject to the FUL in first quarter 2013.
A new and possibly transformative technology for rapidly diagnosing and evaluating patients based on their specific genetic profile may soon begin appearing at retail pharmacies and clinics, giving pharmacists and clinicians another tool for advancing patient health outcomes and their own practice capabilities.
The National Association of Boards of Pharmacy, along with a coalition of healthcare industry stakeholders, on Wednesday issued a consensus statement regarding the collaborative steps that will be taken to help ensure the delivery of responsible and effective patient care as it relates to the prescribing and dispensing of controlled substances.
The Food and Drug Administration’s proposed rule on prescription drug labeling would add $4 billion annually to the nation’s healthcare costs, undercutting the cost savings that generic medicines have brought to America’s patients and healthcare system, according to an analysis released Wednesday by economic consulting firm Matrix Global Advisors.
Endo Health Solutions on Monday announced that its Qualitest subsidiary has completed the acquisition of privately-held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.
The Generic Pharmaceutical Association on Monday identified its key priorities for 2014 — guarding against confusion a proposed labeling change would cause; gaining access to biosimilar generics; and heralding the cost savings generated by generic utilization.
A desire to provide an integrated continuum of care that leads to improved outcomes and patient satisfaction has placed a renewed focus on U.S. hospitals offering on-campus retail pharmacies, according to a report by HealthLeaders Media.
Approximately 1-in-3 chronically-ill National Health Interview Survey participants are unable to afford food, medications or both, according to a study published Jan. 21 in the American Journal of Medicine.
Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.
The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week.
Following the announcement that Rep. Henry Waxman, D-Calif., intended to retire, the Generic Pharmaceutical Association bid adieu to a legislator who had a tremendous positive impact on the generic industry.
The Biotechnology Industry Organization and the Indiana Health Industry Forum commended the Indiana Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.